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ABSTRACT 
One task of the immune system is to distinguish between healthy cells and altered cells due to 
viruses or cancers. To achieve this CD8+ T-cells are constantly monitoring the Major 
histocompatibility class I (MHC-I) complexes expressed on all nucleated cells in the body. 
The MHC-I is basically a scaffold to hold and display a short (usually 8-10 amino acids) 
peptide. These peptides are selected by a complicated machinery from the total peptidome as 
formed by the proteolytic activity in the cells. The peptides derive from the proteome within 
the cells, which is degraded by the proteasome to peptides of various lengths. These are 
transported into the endoplasmic reticulum (ER) by the transporters associated with antigen 
processing (TAP). Inside the ER, the peptides can be further processed by the ER 
aminopeptidases (ERAP1 and ERAP 2) before being loaded into the MHC-I by the peptide 
loading complex (PLC). The peptide loading complex consists of tapasin, ERp57 and 
calreticulin. The peptide MHC-I complex (pMHC-I) is then transported to the cell surface 
where they can be presented to the T-Cells of the immune system. The T-cells express the 
highly variable T-cell Receptor (TCR) which are formed from recombining the V(D)J 
segment in the TCR gene. The T-cells are selected in the Thymus, where self-responding T-
cells are killed and the remaining, with low affinity to self, continue into circulation. This 
ensures protection against autoimmunity, T-cell responses against healthy cells. Cancer-cell 
survival and proliferation require immune system escape and consequently many cancer cells 
have deficiencies in the processing system. 
In this thesis four studies are presented. The first concerns the mechanism of tapasin 
influence on the peptide selection and loading into the peptide binding cleft of the MHC-I. In 
this study, a leucine on a loop of tapasin is shown to be able to bind into the F-pocket of the 
peptide binding cleft, and influence the peptide loading of the MHC-I. 
The second study is about a neoepitope that is presented on TAP-deficient cancer cells. This 
peptide, Trh4, was the first identified TEIPP (T-cell epitopes associated with impaired 
peptide processing). As a murine H-2Db restricted peptide is has an unusual sequence, 
containing four sulphur containing residues of the total nine. Here, we show the formation 
and importance of sulphur-π interaction for complex stability and the unconventional 
methionine at peptide position 5 for the formation of TCR interaction. 
The third study is a follow-up on the second study, but here the immunogenicity of the 
peptide is in focus. While the wild-type Trh4 peptide displays low immunogenicity, the 
mutation of peptide position 3 to a proline significantly increase the immunogenicity of this 
epitope. However, the increased immunogenicity is surprisingly not related to increased 
stability of the pMHC-I complex. 
In the final paper, two virus-associated epitopes are studied due to their differences in 
immunogenicity and binding to MHC-I. Both peptides carry a glycosylation motif and are 
glycosylated in the source protein. Here we show the structural basis for the discrepancy 
between the peptides. The glycosylated residue in one peptide (GP92) is protruding from the 
peptide binding cleft free for interaction with a TCR, while for the other peptide (GP392), a 
glycosylation would hinder the utilisation of a dominant anchor residue of the peptide for 
peptide binding to the MHC-I. 
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1 INTRODUCTION 
1.1 THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I 
All nucleated cells display on their surface the Major Histocompatibility Complex class I 
(MHC-I) proteins. This protein complex, key for the initiation of adaptive immune responses 
against pathogens and cancers, consists of three different chains (subunits); the Heavy Chain 
(HC), the β2-microglobulin (β2m) and a usually eight-to-ten amino acids long peptide. The 
HC is C-terminally anchored in the membrane of the cell and its extracellular parts consists of 
three domains, named α1-α3. The α1 and α2 domains together form the aptly named peptide 
binding cleft (PBC) that binds the peptides (1-3) (Figure 1A and B). The peptides are highly 
varied and are most often derived from proteins degraded within the cell. As such, the 
specific set of peptides on a cell at a single time point, the so-called epitope repertoire, 
mirrors the status of the cell. 
The first discoveries of what later became known as MHC came when George Snell 
published his finding on a genetic locus he named H (for histocompatibility) in 1951. The 
same system was discovered almost simultaneously by Peter H. Gorer who called the antigen 
he studied ‘II’. Both were working independently on the rejection of transplanted grafts and 
tumours. Snell identified the H loci through thorough genetic studies of mice while Gorer 
based his studies on serological characterisation. They both agreed to name the system H2, a 
combination between the names they used. The importance of the H2 genes were published 
in 1951 and marked the start of MHC research (4). In 1975, Zinkernagel and Doherty 
discovered that the MHC genes were the targets of T-cells, which recognised a combination 
of the MHC and an antigen (5-8). The identification of the antigen as being a peptide came in 
1985 by Townsend et al (9), just two years before Bjorkman et al published the first structure 
of the protein (1). The MHC molecules used in the first structural determination were isolated 
from cell surfaces and in combination with the limitations of X-ray crystallography, the 
identity of the occupier of the cleft between the two helices flanking the antigen binding cleft 
was not clear, but as mentioned by Bjorkman et al in their following article, the density 
observed could indeed be representing peptides (1, 2). 
Fundamental to the discovery of the H-2 genes and the properties of the MHC-I is its allelic 
variety, which is the cause of the graft rejection the genes were initially studied for (4). The 
human versions of the MHC-I, commonly referred to as the Human Leukocyte Antigens 
(HLA) A, B and C, together compose above 12´000 alleles according to the HLA 
nomenclature database. Of these, the actual resulting protein variation numbers are 2781 
individual HLA-A, 3501 HLA-B and 2490 HLA-C (10). With such a variety among the 
human population, the task of studying this specific part of the immune system is a great one. 
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1.2 STRUCTURAL ANALYSIS COMPOSITION OF THE MHC-I COMPLEX 
 
As stated above, the MHC-I is a trimeric complex. The HC is the largest subunit, composed 
of approximately 365 amino acids. The protein consists of four domains. The α1 and α2 
domains form the PBC, each forming half of the β-sheet floor and a lining α-helix. The α3 
domain forms an immunoglobulin-like domain under the PBC, and the final section of the 
HC is the membrane anchor. The β2m is a globular protein, folding independently of the HC. 
Last is the peptide in the PBC, usually in an elongated conformation (1). The first structure of 
Figure 1. The general structural 
features of MHC-I 
A. The classical moose 
presentation of the MHC-I 
complex showing the structure in 
the cartoon representation. The 
extracellular domains of the protein 
are indicated and coloured 
differently. B. View from the top 
of the MHC-I showing the peptide 
binding cleft composed of the α1 
and α2 domains with the peptide 
(here in grey stick representation) 
lodged inside. C. A surface 
representation of the top view of 
the MHC-I, without the peptide, 
with the different pockets 
indicated. 
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a MHC-I molecule was published in 1987 (1) and was of the human allele HLA-A*0201. The 
protein was not recombinantly produced, as has commonly been the case later, but was 
produced natively on human cells and cut via trypsinisation. As such, the peptide repertoire 
presented within the cleft of this initial structure was not uniform, and the density within the 
peptide loading cleft did not allow for the identification of a specific binder (1). 
During the studies of the peptide specificity and binding to the PBC, the areas in which the 
side chains of the peptides bind to the PBC were named ‘pockets’. These are categorised A-F, 
roughly aligning with the peptide from the N- to the C-terminus of the PBC (11) (Figure 1C). 
The peptides characterised for each allele have certain common features. The most prominent 
features are the anchor residues, a specific position where one or a few amino acids are 
required for peptide binding. The pockets these anchor residues bind to vary by allele. The 
first study to evaluate the motif of peptide binders for a specific allele was Falk et al in 1991 
(12). In time, as more peptides have been characterised, the motifs have been updated. A 
table with the recent motifs as determined by the Internet Epitope Database (IEDB) (13), for 
some of the most common alleles are shown in table 1. 
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2 PEPTIDE PROCESSING AND MHC-I FUNCTION 
2.1 THE ANTIGEN PROCESSING PATHWAY 
2.1.1 The proteasomes 
The main source of peptides for MHC-I is the proteasome (Figure 2A), a large cytosolic 
complex situated in the cytosol of the cell, with the main function to degrade proteins marked 
for destruction. The 20S core of the proteasome is composed of four rings, with seven 
subunits in each ring, and is the proteolytic part of the complex. The two middle rings consist 
of subunits β1-7 and the two outermost of α1-7. Subunits β1, β2 and β5 possess the protease 
function, cleaving after acidic (caspase-like), basic (trypsin-like) and hydrophobic 
(chymotrypsin-like) residues respectively (14, 15).It is also these three subunits that differ 
significantly in the immunoproteasome, which is a variant that is induced in inflammatory 
processes. In the immunoproteasome, the specificity of proteolytic activity shifts and the 
caspase-like activity is reduced while the cleavage after small hydrophobic residues is 
increased. Interestingly, there is also a so-called ‘intermediate proteasome’ that incorporates 
some of the immunoproteasome subunits in a mix with the normal subunits (16-18). The 
main function of immunoproteasome induction is considered to be to increase the quality of 
the accessible peptides for antigen processing (17). This is a generalisation, however, since 
several immunodominant epitopes are produced by only the constitutive proteasome (19). 
Supporting this generalisation is that when the distribution of the different proteasome 
versions was quantified (18), it revealed high variability in normal tissues, but in the cancer 
cell-lines tested, the variability was notably diminished, with a high abundance of the 
constitutive proteasome and very low levels of the immunoproteasome. 
The proteasome does not only degrade fully functional proteins that have been ubiquitinated 
and elongated, but also Defect ribosomal products (DRiPs) which also are essential to the 
foundations of the peptide repertoire, especially within stressed/infected cells. The DRiPs are 
the main reason for the rapid appearance of disease-associated epitopes prior to symptoms of 
infection in the cell (20, 21). One example of this is the LCMV (Lymphocytic 
Choriomeningitis Virus) nucleoprotein, which was not detectable in the cytoplasm of cells 
within a three days period after infection, while LCMV-derived MHC-restricted antigens 
were detectable on the surface of the infected cells within 45 minutes (22). This and other 
studies proved DRiPs as essential for efficient early cell responses to infection (21). 
2.1.2 TAP peptide transport into the ER 
The ATP-binding cassette-type Transporter associated with antigen processing (TAP) protein 
selectively transport peptides into the ER (Figure 2B). In 1990 the genes of the complex were 
identified as an ATP-dependent peptide transporter situated within the MHC-II encoding 
region (23). Intense work in the following years led to the discovery that the genes encoded a 
heterodimer consisting of TAP-1 functioning as an ATP-binding cassette and TAP-2 
functioning as a peptide translocon (24-32). Interestingly, the binding of a peptide substrate to 
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the TAP transporter does not require ATP. The ATP hydrolysis takes place in the 
translocation step (33). TAP promotes the transfer of 8-16 residue-long peptides (33), with a 
preference for hydrophobic (and for humans also basic) C-termini (28, 34). TAP also favours 
hydrophobic residues in peptide position three and both hydrophobic and charged residues 
are preferred in position two, while N-terminal prolines in positions 1-2 (human) (33) and 1-3 
(mouse) (35) inhibit transport across the membrane. The peptide C-terminus is generally not 
trimmed further within the ER, unlike the N-terminus (36). 
2.1.3 Further peptide trimming mechanisms in the ER 
The main trimming of peptides is done by the protein ERAAP (ER aminopeptidase 
associated with antigen processing) in mice and ERAP1 and 2 (ER aminopeptidases 1 and 2) 
in humans (Figure 2C). These belong to a family of aminopeptidases generally known as the 
oxytocinase subfamily of M1 aminopeptidases. There is an endosomal homologue called 
IRAP (Insulin responsive aminopeptidase) which is regulated by insulin, as opposed to IFN-γ 
for the ERAP proteins. IRAP is mainly involved in cross-presentation, which will be 
discussed further later (37). The ERAPs peptidases usually trim peptides to a length of eight 
or nine residues (38). In humans, ERAP1 has a specificity for hydrophobic and aromatic side 
chains and ERAP2 for long and positively charged side chains (39). Interestingly, the allelic 
variation of both ERAP1 and 2 has a significant influence on the specificity and/or processing 
rates. The overall importance of this trimming step can be illustrated by a 20 % observed 
reduction in the MHC-I cell surface expression upon knocking out ERAAP molecules in 
mice (40). Suggestions that ERAP1 and 2 are trimming the peptides after partial association 
with the MHC-I within the peptide loading complex are contradicted by structural results that 
revealed the distance to the active site in the amino peptidases to be equivalent to six amino 
acids in length from the proteins surface. Such a distance would not allow the optimal 
trimming to make the peptide length 8-10 amino acids, due to sterical hindrance (37). 
2.1.4 The peptide loading complex 
2.1.4.1 Initial folding of the MHC-I heavy chain 
The initial step of MHC-I folding is facilitated by Calnexin (Figure 2D) , an abundant ER 
chaperone, involved in the folding of a variety of proteins (41). The unfolded HC contains a 
N-linked monoglucosylated glycan, the substrate for Calnexin and the related Calreticulin 
binding (42). There is a discrepancy here between the processes in mice and in human. 
Murine MHC-I does not interact with another abundant ER-chaperone, BiP, but human 
MHC-I do. In both cases, however, binding of the already folded β2m causes release from 
these chaperones.  
2.1.4.2 Components of the peptide loading complex 
The MHC-I peptide loading step is facilitated by the multi-protein peptide-loading complex 
(PLC) (Figure 2F), which consists of Calreticulin, ERp57 and tapasin (Figure 2G) all 
supporting the loading and verifying the quality of peptides loaded onto the MHC-I 
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molecules (43). Calreticulin, an abundant ER chaperone, is thought to have a stabilising 
effect on the PLC. It is binds specifically to β2m-bound MHC-I in contrast to the related 
Calnexin (44). Calreticulin knockout affects the repertoire of peptides displayed on the 
surface, both by changing the repertoire of peptides that is displayed and by reducing the 
number of peptide MHC-I (pMHC-I) complexes on the cell surface (45). ERp57 is a thiol 
oxidoreductase that usually cooperates with calnexin and/or calreticulin to assist folding of 
glycoproteins in the ER (46). In the PLC, the function of ERp57 differs. While it still 
interacts with calreticulin, it is also stably associated with tapasin through a disulphide bond 
formed between residue Cys57 within its catalytic site and residue Cys95 in tapasin. As a 
result, this disulphide bridge interaction inhibits the ERp57 oxidoreductase activity. Instead, 
ERp57 has a recruiting role for PLC components, combined with a protective role against 
disulphide bond breakage (46). It contains four domains of thioredoxin type; a b b’ a’. The 
active sites of a and a’ contain the redox activity, while b and b’ are substrate-binding 
domains (47-49). 
Tapasin was first discovered in an experiment investigating the interaction between TAP and 
partially folded MHC-I, where an unidentified 48 kDa glycoprotein co-precipitated with the 
proteins (50). In 1996, Sadasivan et al (51) named this protein tapasin (short for “TAP-
associated glycoprotein”) and showed it to link TAP to MHC-I before peptide binding. The 
protein is a type I transmembrane protein composed of 428 amino acids. It has a single N-
linked glycosylation site and an ER retention signal (52, 53). 
Tapasin stabilizes the open forms of peptide-deficient and peptide-filled class I molecules, 
thereby likely diminishing the energy barrier that bound candidate peptides must overcome in 
order to stable binding to in the class I binding groove (54). Interestingly, tapasin binds to 
TAP through interactions within the ER transmembrane regions. The N-terminal 
transmembrane helix from both TAP 1 and TAP 2 are interacting with tapasin (55). Tapasin 
association with TAP affects TAP levels in some cell types (56), with as much as a threefold 
increase reported for some cell lines. Soluble tapasin does not associate with TAP, but 
restores the surface levels of MHC-I compared to tapasin deficient cells (57), indicating that 
the most essential role of tapasin is the peptide loading and selection. 
2.1.4.3 The 721.220 tapasin-deficient cell line 
Many studies on the function of tapasin have been performed on the lymphoblastoid 721.220 
cells. This cell line has a mutation that causes exon 2 to be spliced out and exon 1 and 3 to be 
annealed to each other. While this alternative splicing is detected in wild type cell lines, it is 
only detected at the nucleic acid level and not as a produced protein in the wt cells. Both are 
detected in the 721.220 cell line. The result is a 57-amino acid deletion, which abrogates 
MHC-I association but not TAP association (58). In 721.220 cells the surface expression of 
MHC-I is therefore 20-25% compared to normal cells. Since the TAP-association is still 
intact in these cells (59), this means that the cell surface expression levels reflect the loss of 
interaction between tapasin and the MHC-I, as well as possibly ERp57. Tapasin double 
knock-out mice display a 80-85% reduction in the amount of peripheral T-cells and the 
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MHC-I surface levels cells in these mice are 10-15% compared to wild-type (WT) levels, 
which is approximately double the levels observed on TAP double knock-out mice (56).  
The first 50 N-terminal residues of tapasin are essential to the assembly of the PLC and its 
association with TAP (60), even though this association takes place in the C-terminal TM 
(transmembrane) region (55), according to a study by Bangia et al 1999. There is however a 
problem with this study of the 50 N-terminal amino acids, since there are no controls 
described in the paper, determining if truncation affects the structural integrity of the 
remaining protein (60). This means that the observed effect could be a result of full or partial 
misfolding of the protein and thereby a complete loss of tapasin. Furthermore, there was no 
positive control example of an interacting truncate, but instead the positive control was the 
full-length protein. Interestingly, there is a later study on a melanoma-associated tapasin 
mutant lacking the third exon, representing amino acids 70-156, which includes the Erp57 
interacting site. This truncation did not affect the MHC-I surface levels to the same extent, as 
measured using the same tapasin-C-terminal restricted antibody (61). This study displayed 
the same issues as the previous, with no discussion or reflection of the possibility of a 
partially or completely misfolded tapasin. These studies are further compromised when 
considering that tapasin association with TAP affects TAP levels in some cell types (56), with 
as much as a threefold increase reported for some cell lines. This renders the results even 
more difficult to interpret. Are the apparent effects of the tapasin because of these deletions 
due to the loss of tapasin structural integrity, the loss of the amino acids described or due to a 
secondary effect on TAP, which is essential to peptide import? More studies will be needed 
to determine the answer to these questions and the use of an antibody specific for the 
correctly ER-lumenal domains would be essential. (62, 63).(64, 65) (66, 67).(68, 69).(70-72) 
  
  
Figure 2. The antigen processing pathway 
A. The peptides originate from the products of the proteasomal (teal colour) degradation of the 
proteins from the cell. B. These are selectively transported by TAP (purple) into the 
Endoplasmic Reticulum (ER). C. The peptides can undergo further trimming by the ER 
aminopeptidases (ERAP 1 and 2, grey and dark grey) and the final peptides of an adequate 
length (dark blue) can compete for loading into the peptide binding cleft of the MHC-I. D. In the 
ER, the HC of the MHC (red) are stabilised by calnexin (CNX, light green) until the binding of 
β2m (pink). E. As β2m binds, CNX releases the peptide-receptive MHC-I (MHC-I pr). F. The 
MHC-I pr binds to the peptide loading complex (PLC). G. The PLC consists of tapasin (light 
blue), ERp57 (orange) and calreticulin (CRT, dark green) as shown in the insert. When a peptide 
binds, the PLC releases the loaded MHC-I. Either in the ER (H.) or in the Golgi (I.), the peptide 
loaded MHC-I can be further checked by TAPBPR (cyan), who in the case of suboptimal 
peptide loading can dislodge the peptide. The TAPBPR can also interact with the UDP-
glucose:glycoprotein glucosyltransferase 1 (UGGT 1, brown) who is can reattach the glycan 
needed for CRT interaction and thereby recirculate the MHC-I pr back to the PLC. J. If the 
MHC-I passes the check of TAPBPR, and has an optimally loaded peptide, it can continue to the 
cell surface. 
The structures shown in the figure are based on PDBcodes 6ENY (62) (PLC, CNX and MHC-I 
pr), 1PMA (63) (proteasome), 5U1D (64, 65) (TAP), 2YD0 (66) (ERAP 1), 3SE6 (67) (ERAP 
2), 5OPI (68) (TAPBPR including bound MHC-I), 5JWD (69) (MHC-I). The UGGT1 structure 
is predicted by the RaptorX structure prediction server (70-72). 
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2.1.4.4 Interactions within the peptide loading complex 
The crystal structure of the tapasin-ERp57 complex has been published in 2009 combined 
with a site-directed mutagenesis investigation of the interactions of this complex with MHC-
I. Within the PLC tapasin exists as a heterodimer with ERp57, linked via a disulphide-bridge 
between residues Cys95 of tapasin and Cys57 of ERp57 (73). The crystal structure revealed 
an L-shaped tapasin, and the interaction sites with MHC-I were determined to be close to the 
angle of the L. The U-shaped ERp57 is on the opposite side of tapasin, meaning that it is 
likely not directly interacting with the MHC-I molecule. There are several loops in the crystal 
structure of tapasin that are missing due to high mobility, including one loop situated near to 
the modelled MHC-I (73). This positioning was confirmed recently, when the first structure 
of the PLC was published (62). The method of structural determination was single particle 
electron cryo-microscopy (Cryo-EM) and the maximum resolution at 5.8Å was enough to 
determine the spatial positioning of the complex but provides little information on the side 
chains or sometimes even general main chain positioning. It did however reveal a few 
important surprises. While it was previously well established that each TAP molecule can 
interact with two tapasin molecules (74), it was not known until now that the two tapasin 
molecules interact with each other. Neither was it known that ERp57 and calreticulin bind 
across the two copies of the mega-complex (62).  
2.1.5 Post PLC processing 
In the year 2002, a new player in the peptide loading mechanism was discovered (75), located 
genetically in a region associated with MHC-I (76, 77). Named TAPBPR (for TAP-binding 
protein related), it had 33% similarity and only 22% sequence identity with tapasin (75). 
Unlike tapasin, its location is not restricted to the ER as it lacks the ER retention signal. 
Indeed, 10% of the expressed TAPBPR is located at the surface of the cell (75) and 50% of 
TAPBPR molecules show evidence of Golgi processing in a study by Boyle et al, meaning 
that they at some point have passed through or recycled from the Golgi Network (78). This 
was confirmed in the first follow-up study seven year later (79). It would be a total of eleven 
years, however, before further studies were published, when in 2013 Boyle et al reported 
TAPBPR to be implicated in peptide loading (78). It had no association with the PLC, and the 
binding to MHC-I was competing with tapasin, meaning that the interacting surface of these 
two proteins on the MHC-I overlap (80). TAPBPR is a peptide exchange catalyst (81, 82), 
and in absence of TAPBPR the bound peptides of MHC-I at the surface of the cells average a 
lower affinity than in the wild type equivalent (81). As TAPBPR associates with the low 
affinity peptide-loaded MHC-I it recruits the UDP-glucose:glycoprotein glycosyltransferase 
1, responsible for adding a glucose to the glycan of MHC-I (and other proteins) hence halting 
their transport to the surface and promoting association or re-association with the PLC. UDP-
glucose:glycoprotein glycosyltransferase 1 is resident in the ER and the cis-Golgi (83, 84). 
Together with the evidence mentioned earlier of TAPBPR presence in the Golgi, it seems 
likely that TAPBPR is a direct player in the recycling of sub-optimally loaded MHC-I 
between ER and Golgi (Figure 2H and 2I) (85). 
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2.1.6 Peptide selection and editing by tapasin and TAPBPR 
Supported by the newly published structures of TAPBPR in complex with MHC-I (68, 86) 
and the PLC cryo-EM structure (62), in combination with paper I within this thesis, it is now 
possible to draw conclusions about the peptide loading mechanisms. The two structures of 
TAPBPR have certain things in common: 1) they are both low resolution structures at 3.4Å 
(Jiang et al. (86)) and 3.3Å (Thomas and Tampé (68)); 2) they both illustrate the use of the 
“jack hairpin” (named by Thomas and Tampé) to bind underneath the β-sheet floor of the 
PBC; 3) both structures show a widening of the PBC by a lateral movement of the α2-helix. 
There are however still controversial issues in both structures, namely the interpretation of the 
positioning of the side chain of the MHC-I residue Y84, which is involved in peptide C-
terminal binding. Both structures claim that the side chain of this residue flexes out from the 
PBC and interacts with residue E105 in TAPBPR. At this resolution interpreting the exact 
positioning of a side chain can be devious, especially in the Thomas and Tampé structure, 
where the statistics of the structure are rather poor, indicating that the actual resolution is 
significantly worse than 3.3Å. When calculating the omit maps for both these structures, it is 
revealed that the density of the Y84 sidechain is weak. A significant difference in the two 
structures is the visibility of a loop from TAPBPR which in Thomas and Tampé’s structure 
are inserted into the F-pocket area of the PBC. In the Jiang structure there is some density in 
this area, but not enough for accurate modelling of even the main chain. The Jiang structure 
also includes a peptide in the N-terminal part of the PBC, bound to a mutated Cysteine on 
position 73 of the α1-helix, while the PBC of the Thomas and Tampé structure has an empty 
PBC. In paper I new results are presented on the molecular mechanism behind the peptide 
editing effect of tapasin.  
2.2 ATYPICAL ANTIGEN PROCESSING 
2.2.1 Antigen cross-presentation 
Cross-presentation of exogenous antigens on MHC-I is a process that still needs lots of 
investigation, since many steps are not fully understood and there are several pathways 
working simultaneously. The main cell type where this phenomenon has been found is the 
dendritic cell (DC), but other cell types such as macrophages, mast cells, epithelial cells etc… 
can also exhibit cross-presentation (87). There are two main pathways, the dominant 
phagosome-to-cytosol (P2C) and the minor vacuolar pathway (88). 
2.2.1.1 The phagosome-to-cytosol pathway 
In the phagosome-to-cytosol pathway the exogenous antigen source is taken up by a 
phagosome. As this pathway requires the use of the proteasome, the antigen must be 
translocalised from the phagosome into the cytosol. The pathway for this transport is yet 
debated, but there have been suggestions that ERAD, the ER-associated degradation pathway, 
is involved. ERAD proteins can be transferred into the phagosomes, together with other ER 
proteins such as TAP. Alternatively, phagosomal disruption, involving the collapse of the 
phagosomal membrane and the release of the contents into the cytosol, is a possible 
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mechanism (87, 88). The loading of the peptides is then expected to follow either the 
traditional antigen processing pathway or taking place in phagosomes. In the phagosomes, the 
source of the MHC-I is still not completely clear. A very popular option is that internalised 
MHC-I from the cell surface is re-used, which is supported by the fact that these MHC-I 
molecules are EndoH-resistant, meaning they have passed through Golgi and not been 
transported directly from the ER (87, 89). Tapasin, which contains an ER-retention signal, is 
not likely to be present in phagosomes (53). Recently, suggestions for TAPBPR involvement 
in this step have been made (83). 
2.2.1.2 The vacuolar antigen pathway 
The vacuolar pathway is independent from TAP and the proteasome. Instead the proteolysis 
and the peptide loading occur within the endocytic compartment. In this pathway the 
proteolysis is mainly performed by cathepsins that are induced by acidification after 
endosomal fusion with phagosomes. Another component of the degradation pathway is 
IRAP, (insulin-regulated aminopeptidase), an aminopeptidase recruited to phagosomes and 
that is regulated by both insulin and IgE immunoglobulin. It has a broad specificity, equal to 
ERAP1 and 2 combined and, as such, can mimic the function of the ERAPs in the endosomal 
compartment (39). 
2.2.2 Post translationally modified peptides 
Several types of post-translational modifications (PTMs) have been identified on MHC-I 
peptide epitopes. These include acetylation (90), cysteinylation (91), deamidation (92), 
glycosylation (93-97), methylation (98), nitrotyrosinylation (99, 100) and phosphorylation 
(101-103). The most well studied of these PTMs are glycosylations and phosphorylations.  
Glycosylations identified in the context of MHC-I are either O-linked or N-linked. The third 
type of constitutive glycan, glycosylphosphatidylinositol (GPI) anchors have to my 
knowledge not yet been shown as a MHC-I binder. However, while potentially N-
glycosylated peptides have been identified, none have yet been eluted still carrying the glycan 
(104). The O-linked glycans bind to either serine or threonine without any sequence 
specificity, unlike N-linked glycans which bind to asparagine within Asn-X-Ser/Thr where X 
≠ Pro. The O-linked glycans are more varied, while the N-linked specifically consists of an 
initial N-acetylglucosamine (GlcNAc) moiety. O-linked glycans have been shown to be 
transported through TAP into the ER. N-linked glycans are still a mystery. N-glycosylations 
are known to affect proteasomal degradation of surrounding epitopes (105). The glycan can 
be cut prior to the proteasome processing by peptide N-glycanase, causing the mutation of the 
encoded asparagine N to a glutamate D (106), potentially causing the lack of eluted N-linked 
glycopeptides. Reasonably, the large glycans would not be anchoring into the PBS and 
indeed structures (107), predictions (97) and described glycan-restricted T-cells (93, 108) 
corroborate this. In some cases, however, the glycan does not protrude from the MHC-I PBC. 
This is the case in the binding of MUC1.-8-5GalNAc, which utilises the monoglycan as an 
anchor when binding to H-2Kb (109). 
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Phosphorylation is a fairly small PTM, but highly important in the energy homeostasis in the 
cell. Phosphorylated peptides are transported by TAP into the ER (110). Ser and Thr 
phosphorylated peptides are the most common to be identified on MHC-I (111), but 
phosphorylation can take place on Tyr and His also (112). A recent study (113) identifying 
peptides found in melanoma from patients, found 365 HLA-I restricted phosphopeptides and 
25 restricted to HLA-II. Of these 78 % were phosphorylated on Ser, 19% on Threonine and 3 
% on Tyrosine (113). The phosphorylation site of the peptide is usually at position P4 of the 
peptide (102). 
2.3 THE αβ-T-CELL RECEPTOR 
2.3.1 Education 
T-cells are educated in the Thymus, mainly early in life from the neonatal period to puberty 
(114). The T-cell expresses a randomly generated T-cell Receptor (TCR) and its sequence is 
determined by the randomized recombination of the V, D and J gene segments for the β-chain 
and the V and J segments for the α-chain. The differentiation to either a CD4+-expressing 
(MHC-II restricted) or CD8+-expressing (MHC-I restricted) T-cell is done according to their 
affinity for either MHC class in the cortex, combined with the expression of a large ensemble 
of cytokines (115, 116). The first step in the T-cell education is the positive selection, which 
takes place in the cortex of the thymus, where cortical thymic epithelial cells are presenting 
peptides both on MHC-I and MHC-II (117). The selection of the peptides for both classes is 
aided by proteases uniquely expressed in these cell types (116). In the presentation pathway 
for MHC-I a third form of the proteasome, the thymoproteasome, is present. While the β1 and 
β2 subunits in the thymoproteasome are the same as in the immunoproteasome, the β5 
subunit is unique and contains a hydrophilic residue in the middle of its hydrophobic binding 
site. This causes a weakened chymotrypsin activity, affecting the positive selection of T-cells 
during thymic education (118). The purpose and reason for this discrepancy of peptides 
expressed during the positive and later the negative selection is still debated (119, 120). The 
positively selected T-cells move thereafter on to the thymus medulla, while the cells removed 
from further education undergo “death by neglect” (121).  
In the medulla, the negative selection occurs, with the eventual removal of self-reactive T-
cells that could cause autoimmunity. In contrast to the process of positive selection, there are 
more than one kind of APC present, both medullar thymic epithelial cells (mTECs) and bone-
marrow derived dendritic cells, and the proteasomes are the constitutive and 
immunoproteasome (115). The negative selection endpoint is the removal of autoreactive T-
cells, which occurs upon T-cell interaction with the self-peptides expressed on the APC in the 
medulla. Essential to this selection is the expression of tissue specific antigens, usually 
restricted to a specific tissue type, meaning that the mTECs have promiscuously expressed 
proteins that are usually downregulated outside a specific tissue. Interestingly, only 1-3% of 
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(122, 123) 
the mTECs produce each tissue specific antigen. They do get help from DC though, by 
secretion into the extracellular space and normal DC uptake and presentation. Eventually, the 
remaining T-cells are tolerant to the self-antigens and non-immunogenic in the uninfected 
milieu (124). 
β1 
β2 
β3 α3 
α1 
α2 
A B 
C 
TCR 
MHC-I 
Figure 3. The classical areas for TCR CDR-loop landing on the MHC-I 
A. The regions where the CDR loops most commonly land on the MHC-I are indicated in 
different colours. These colours are the same throughout the figure. B. Overall view of the TCR 
on top landing on the MHC-I below. The MHC-I is angled with the C-terminal region of the 
PBC towards the viewer. C. Zoom in on the CDR loops of the TCR and the PBC with the 
peptide in green. While this is a general pattern, based on the report by Attaf et al 2015 (122) 
there are examples of reversed polarisation where the chains change place. The structure of the 
TCR-MHC-I is based on PDBcode 2BNR (123).  
  15 
2.3.2 Recognition on T-cell epitopes and modes of interaction 
Each chain of the TCR has three MHC-I interacting loops, named complementarity 
determining regions (CDR) 1, 2 and 3. CDR 1 and 2 are encoded by the germline in the T cell 
receptor alpha and beta variable (TRAV and TRBV) regions. The CDR3 loops are the 
hypervariable regions encoded by the V, D and J segments as described above. The 
difference in the variability between the interacting loops are reflected in regions of the 
MHC-I where these typically interact. While there are exceptions (125), the CDR 1 and 2 
loops mainly interact mainly with the α-helices of the MHC-I and the CDR3 loops with the 
peptide, making the hypervariability of the CDR3 mirrored by the versatility of the peptide 
bound in the cleft of the MHC-I (122) (Figure 3). 
Interestingly, immunogenic differences in the TCR-MHC-I interactions have been difficult to 
correlate with major structural changes in the interaction. While this remains a mystery, the 
complicated system that is the in vivo environment of the interaction provides many different 
additional factors to the equation. The MHC-I specific TCR expresses a co-stimulatory 
molecule known as CD8 (the equivalent is CD4 for MHC-II). This complex protein stretches 
next to the TCR and interacts with the α3 domain of the MHC-I heavy chain (126). Besides 
the TCR and the CD8, the T-cell also express the CD3 complex, with co-stimulatory 
functions partly responsible for initiating the immune response. It is the phosphorylations of 
the CD3 complex which initialises the signalling cascade inside the T cell following the 
activation (114). These (the MHC-I, TCR, CD8 and CD3) form the centre of what is the 
immunological synapse. How exactly small changes in the MHC-I due to minor changes in 
the peptide (such as the case in paper III), can cause marked differences in the immune 
response is still not completely clear. Other factors that have been suggested for fine-tuning 
of the immune-response is clustering of co-stimulatory molecules and/or TCRs and/or MHC-
I on the cells. 
Perhaps the two main models for how the TCR interacts with the MHC-I can give further 
clues to the difficulties in finding structural correlations to immunogenicity. These are called 
the “standard model” and the “tritope model”. Simply, the standard model considers the 
MHC-I surface as one antigenic entity, similarly to an epitope of an antibody. The TCR 
surface would also be considered as one interacting surface that cause differential signals 
depending on the quality (length, occupancy, avidity etc) of the interaction. This model is 
most used by structural biologists and immunologists (127, 128). The tritope model considers 
the MHC-I surface as three different epitopes. The first one of these is the thymic antigen site, 
which is selected for during positive selection, and can be considered the recognition of the 
MHC-I as a molecule. The second is the allogeneic epitope, recognising the allele itself, and 
the cause for graft-vs-host immunity responses that occur in MHC-I allele mismatched 
transplants. The last epitope is the peptide epitope and the cause of the specificity of the 
TCR-pMHC-I interaction. The idea is that the CDR 1 and 2 loops interact with either of the 
first two epitopes and the CDR3 loop interacts with the peptide. The interactions would then 
cause a conformational change that would initiate the signalling cascade for T-cell activation. 
The tritope models’ main advocate is Professor Melvin Cohn of the Salk institute (127).  
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While both these models have advantages/disadvantages, the standard model could explain 
the lack of conformational changes seen in some pMHC-I complexes with different 
immunogenicity but identical structures by instead focusing on, for example, the interaction 
length or occupancy. This can be difficult to explain with the tritope model, which would 
indicate that the peptide only is recognised by the CDR3 loops and thereby would make little 
differences if the conformations would change. The interacting regions of the TCR as seen in 
figure 3 does however support the tritope model, with the CDR loops main interaction sites 
agreeing with the hypothesis (with that said, it does not disagree with the standard model). 
Cohn seems unwilling to recognise that reality might be a compromise between these models 
(127, 129), but as increasing numbers of studies of specific TCR-pMHC-I interaction are 
published the conclusions might lead in either direction. 
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3 NEOEPITOPES AND IMMUNE THERAPY POTENTIAL 
3.1 VIRAL IMMUNE ESCAPE STRATEGIES 
Evolution has caused viruses to utilize several mechanisms to escape immune detection by 
interfering with the MHC-I molecule or the antigen presentation pathway. Several 
independent strategies are present, and it is not uncommon for the same virus to utilize 
several different mechanisms simultaneously (130, 131). The US3 transmembrane protein 
from HCMV (Human Cytomegalovirus), for example, has been shown to inhibit the peptide 
editing function of tapasin and bind and detain MHC-I in the ER (132, 133). Herpesviruses, 
the family to which HCMV belongs, have evolved various manners to inhibit the antigen 
presentation to T-cells. Viruses in this family have been shown to shut down cellular 
synthesis of MHC-I, initiate degradation of produced MHC-I complex (134) and inhibit 
several proteins in the peptide processing pathway in using a variety of mechanisms (130). 
Inhibiting proteins in the antigen processing pathway is also a common strategy for other 
viruses such as papilloma viruses (135) and poxviruses (134) which are interfering with TAP 
function which is a highly used strategy for herpesviruses. These strategies are also hinting to 
cancer immune escape strategies. As cancers are pathogenic transformations of cells, the need 
for these to escape the immune surveillance is just as necessary as viral escape for survival 
and progression. 
3.2 CANCER ASSOCIATED EPITOPES 
Cancers cause and are caused by malignant transformations of the cells. In order for a cancer 
to progress, the transformation needs to go under the radar of T-cells and other immune cells. 
There are at least five different types of peptide antigens classified, which are collectively 
known as tumour-associated antigens (TAA). These are mutated antigens, cancer-germline 
gene encoded antigens, peptides derived from oncogenic viruses, differentiation antigens and 
tumour over-expressed antigens (136). The names are indicative of the processes in which 
these antigens appear. The mutated antigens appear because of mutations within the cancer 
cells. Depending on the mutation, the resulting neoantigen could be the result of either a 
frameshift, causing new amino acid sequences to occur, or a point mutation. Even if this is a 
promising source of cancer-specific antigens, the mutational variability in different patients 
and cancer-types complicated the development of therapeutics (136, 137). Cancer-germline 
encoded antigens stem from genes that are turned off by methylation in all cells except male 
germ cells (138). As such, they are supposedly highly tumour-specific, but recently this has 
been questioned due to the discovery of low level expression of the cancer-germline epitope 
MAGE-A12 on brain cells, with lethal consequences in immunotherapy trials (139). Peptides 
from oncogenic viruses are promising candidates to use for T-cell based immunotherapies 
(140). The problem with these though, is that these viruses, such as papilloma viruses, usually 
are equipped with immune evasion strategies to avoid detection as discussed above. 
Differentiation antigens are derived from proteins that are present in a very small number of 
tissues. The most studied antigens in this group are the peptides derived from melanin 
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production in melanocytes in the skin, often present in malignant melanoma (137). Targeting 
these antigens have proven to give rise to side effects such as vitiligo and melanocyte death in 
the eyes (141). Overexpressed antigens, derived from proteins that are upregulated in the 
cancer cell, have the most obvious drawback in that they are present on healthy cells to some 
amount. This leads to two problems; Quantifying the overexpression in comparison with 
normal cells and the possibility of an induced T-cell response targeting both pathogenic and 
benign cells. While each of these antigen groups presents different challenges, two are 
general. At the molecular level, to overcome tolerance without modifying the epitope 
conformation in compared to the wild-type can be problematic, since too radical 
modifications might not allow cross-reactivity with the wild-type complex. It is also well 
established that upon breaking tolerance to one of these antigens, there is a great risk that the 
antigen is present on another cell type in the body and thereby any response to the tumour 
will also directly target healthy cells (136, 137). Thus, an ideal TAA should be a true 
neoepitope.  
3.3 NEOEPITOPES 
3.3.1 Cancer neoepitopes 
Neoepitopes, neoantigens or neopeptides are all names used for peptides that are uniquely 
presented on cells that have some form of unwanted transformation, such as a virus or cancer. 
Of the TAAs described above, mutated antigens and antigens from oncogenic viruses classify 
as neoepitopes. These are however not the only possibilities for neoepitope formation. 
Mutations in cancer can affect proteins without forming a new epitope and instead cause 
secondary effects such as modified PTM patterns or loss of function of important proteins in 
the peptide processing pathway, similarity to escape-strategies by viruses. 
In the case of PTM’s two recent examples of identified neoepitopes are promising. Malaker 
et al. recently characterised glycosylated neopeptides from various types of leukemia. They 
discovered that several identified peptides were present in more than one patient, even within 
different types of malignancies (142), providing promising possibilities for a broad treatment 
based on these glycosylations. Another study identified methylated peptides (98). A portion 
of the identified epitopes was derived from proteins associated with cancer, and some of the 
peptides were derived from proteins directly involved in aggressive breast cancer. 
To ensure adequate CTL recognition of cancers and/or viruses, the PLC system needs to be 
fully functional. Immune evasion strategies may cause defects in the peptide processing 
pathway and down-regulation or eradication of the involved proteins can occur, resulting in 
failed clearance of malignant cells. Deficiencies in the antigen presenting pathway, i.e. TAP-
deficiency, tapasin-deficiency etc, is common in poor prognosis and metastasis-prone cancers 
(143). However, certain deficiencies in the antigen processing machinery have been shown to 
instead cause the formation of a specific kind of neoepitopes that show great promise for 
therapeutic use (144). 
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3.3.2 T-cell epitopes associated with impaired peptide processing 
The existence of T-cells that react efficiently towards TAP-deficient cells was established in 
1991 (145), when Aosai et al identified TCR clones that elicited CD8-dependent responses 
against both murine lymphoma cell line RMA and the TAP-deficient clone RMA-S. At the 
time, the authors concluded that there must be T-cell clones specific for peptide-free MHC-I, 
since the RMA-S clone, due to its TAP-deficiency, was suggested to be devoid of the pMHC-
I complexes (146). In 1997, Wolpert et al (147) studied the immune response against RMA-S 
cells in the C57BL/6 mouse model. While these cells escaped immune recognition, the RMA-
S.B7 transfectant induced responses against RMA-S targets. B7, or CD80, is a co-stimulatory 
T-cell activating signal molecule. These responses needed MHC-I expression and TAP-
deficiency, but not until a study in 1999 was it evident that the “empty” MHC-I molecules on 
the RMA-S cells were occupied by low affinity peptides (148).The nature and identity of 
some candidates within this processing-impaired-associated peptide repertoire were not 
elucidated until 2006 in a breakthrough study performed by van Hall et al (149). These T-cell 
epitopes associated with impaired peptide processing (TEIPP) are true neoantigens that are 
efficiently recognized by specific T-cells, and are only presented on TAP-, tapasin- and/or 
proteasome-defect cells, and not on corresponding normal cells. The first identified TEIPP 
peptide was derived from a ceramide synthetase called Trh4, which also became the name of 
the peptide. Interestingly, this peptide is derived from a minor splicing product of the Trh4 
gene which causes a frame shift and early stop-codon. The expressed peptide sequence is 
localized at the C-terminus of the Trh4 protein, which protrudes into the ER where it is cut by 
a signal peptide peptidase, thus a product of the less common alternate peptide processing 
pathways (149-151). This epitope and its binding to the murine MHC-I allele H-2Db is 
studied in papers II and III. TEIPP epitopes are promising new targets for immune-based 
cancer therapies (143, 144). Importantly these epitopes do not participate in the thymic 
tolerization process. In TAP-deficient mice, the thymus selection process deletes T-cells that 
are specific to MHC molecules in complex with self-peptides, leading to tolerance. In TAP-
proficient thymoid cells, these TEIPP-specific T-cells were indeed selected, meaning that 
they can clearly be used in immunotherapies (143). 
3.3.3 Peptide processing in deficient cells 
TAP-deficient cells were initially suggested to be void of any peptide-filled MHC-I on the 
surface of the cells, and hence was termed “empty” (146). It was soon discovered this was not 
the case and that these MHC-I complexes instead were associated with low affinity peptides 
(148, 152, 153). A common cause for CTL evasion is often the loss of TAP function, found 
in a variety of tumour cells (154) such as the RMA-s cells initially studied (146). As the 
peptide flow into the ER is significantly impaired, the levels of pMHC-I complexes on the 
surface of these cells are often reduced to less than 10 % of the normal levels (146, 155, 156). 
If TAP is not the source of peptides in these cells, where do they come from? Preliminary 
suggestions for the potential origin of these epitopes were signal peptides or TAP-
independent, unidentified mechanisms of import (148, 152, 157). It is however now well-
established that these peptides are derived from ubiquitously expressed house-keeping 
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proteins and represent a truly novel repertoire of neoantigens that appear only on antigen-
processing-impaired cells (149, 150). It should also be noted that following functional knock-
down of TAP, a large portion of the presented peptides are still processed by the proteasome, 
suggesting alternative routes for processing that involve endosomal and vesicular 
compartments. Many of these neoantigens also result from degradation by metalloproteases, 
known as endoproteases, while a relatively small number of neoantigens derive from 
previously known proteases in the ER and Golgi, such as furins and signal peptide peptidases 
(150). Until very recently, it was believed that the only protease capable of cutting the 
peptides C-terminally was the proteasome. This view has been challenged, and one example 
is a study by Kessler et al. (158) that shows the need of nardilysin and thimet oligopeptidase 
in the C-terminal trimming of the PRAME tumour antigen. Although these results provided 
new information on C-terminal trimming, a knock-down of the pathway gave little effect on 
MHC-I levels, indicating that this pathway is not alone responsible for proteasome deficient 
peptide production (158, 159). In a study of HLA-A2 and HLA-B51 associated peptides in 
TAP-deficient cells (160), 75% of the identified peptides were derived from signal sequences. 
Interestingly, many of these did not have the C-terminal sequence of the signal peptide, 
indicating further C-terminal trimming. In the same study, it was concluded that the 
presentation of the non-signal-sequence peptides mainly were inhibited by using proteasome 
inhibitors (160). There is a possibility that proteasome independent protease-processing has a 
different influence over different cell types. The knock-out of the abundant PSA peptidase 
caused a 25% increase of surface MHC-I on DCs but had no effect on B or T lymphocytes or 
fibroblasts (161). There are indications that endolysosomal uptake and transport of the 
peptides are involved in TAP-independent pathways, as blocking of endolysosomal 
acidification in TAP-deficient cells increased the surface expression of a TEIPP epitope 
(150). 
Oliveira et al showed that inhibition of the proteasome decreases levels of H-2Kb and H-2Db 
by between 40 and 55%. While they claim that their results demonstrate that most TAP-
deficient epitopes derive from the proteasome (150), it should be interpreted with caution. 
The inhibitor used in the study, epoxomicin, is an inhibitor of the chymotrypsin-like activity 
(159). While the MHC-I level decrease illustrates reduction, its definite level can be 
misleading since the specificities of the H-2Kb and H-2Db alleles both favour hydrophobic 
amino acids (12) in the C-terminal. As such, the reduction of MHC-I levels might have been 
less if the trypsin or caspase activity was inhibited, and the absolute level of peptides derived 
from the proteasome might be larger than the numbers indicate for these alleles. Proteasome 
independence is difficult to study. Commonly the methods of study have included the use of 
different proteasome inhibitors. These might give unexpected effects, as described in an 
excellent review by van Endert (159), inhibition of only parts of the proteasome function can 
cause a shift in proteasome efficiency causing an apparent independence. Also, inhibition can 
cause epitopes to appear that would otherwise have been destroyed by proteasome activity, 
making them appear to have been cut by other proteases (159). However, the peptides 
appearing in these cases, that would not appear with normal proteasome function, can be 
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thought of as neoepitopes and can be used to illustrate the changes in a proteasome with 
naturally occurring deficiencies. 
3.4 ALTERED PEPTIDE LIGANDS 
The first-time usage of the phrase “altered peptide ligand” (APL) as a term for mutated 
peptides was in 1993 by Evavold, Sloan-Lancaster and Allen. They suggested that the 
definition would be “analogues of immunogenic peptides in which the TCR contact residues 
have been mutated” (162). In time, the term also came to include any single modification of a 
MHC-I binding peptide used to influence the immunogenicity. In designing therapeutic 
treatments, this strategy has been very popular. The common aim is to break T-cell tolerance 
of a cancer- or virus-associated epitope.  
APLs have been utilised frequently through the years. Commonly, the strategy has been to 
increase the affinity or stability of the pMHC-I complex (163-165). Harndahl claims in a 
study from 2012 that stability is a better predictor than affinity for prediction of 
immunogenicity (164, 165). This would logically make sense, since higher pMHC-I stability 
would lead to the pMHC-I being present longer on the cell-surface, hence giving the TCR 
more time to recognise it. While this strategy has worked beautifully (166-168) it is not 
always true. Examples of APLs that have increased affinity or stability but still not being 
recognised have been proposed and alternative rules suggested (169, 170). In paper III of this 
thesis we describe an APL with significantly increased immunogenicity, but lower 
stabilisation capacity (171). There have also been descriptions of large structural shifts 
induced by these APLs, potentially causing the altered immunogenicity, but equally so, there 
are examples where the conformations of TCR interacting residues remain essentially 
unchanged. Conclusively, even with all the studies in the area, the exact biophysical bases 
behind increased T-cell recognition remains a mystery to be further studied. 
 

  23 
AIMS OF THIS THESIS 
To increase the understanding of the molecular mechanisms behind peptide editing by tapasin 
in the peptide loading complex. 
To understand the unconventional H-2Db-restricted TEIPP epitope Trh4 at a molecular level 
and apply the p3P mutational approach on an Trh4 APL to increase its immunogenicity. 
To investigate the contradictory effect of glycosylations on two different viral epitopes 
restricted to H-2Db. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I – SUCCESSIVE CRYSTAL STRUCTURE SNAPSHOTS REVEAL 
THE BASIS FOR MHC CLASS I PEPTIDE BINDING AND EDITING 
This paper starts with the crystal structure of H-2Kb in complex with only a dipeptide, GL. 
This peptide was previously shown to stabilise the complex and promote peptide exchange of 
MHC-I (172, 173). The structure of H-2Kb/GL was determined using X-ray crystallography 
to a resolution of 1.8Å (Paper I, S.Tab. 1). The asymmetric unit of the crystal contained two 
complexes, both with the GL peptide bound to the F-pocket of the PBC. The rest of the cleft 
is open and contains a few waters (Paper I, Fig. 1A and 1B). Interestingly, the α-helices 
lining the PBC take the same configuration when binding GL as when binding the canonical 
high affinity binding peptide SEV (FAPGNYPAL) (174). Previously to this structure, the 
shortest peptide a MHC-I has been structurally characterised in complex with is the SEV C-
terminal pentamer NYPAL (175). The NYPAL epitope was in complex with the H-2Db allele 
and while the C-terminal leucine did act as an anchor, the N-terminal asparagine, did not 
fulfil its canonical role as an anchor. While surprising, this reveals the importance of the N-
terminal to induce the observed conformation of the full-length SEV peptide. The 2.3Å 
structure in paper I of the H-2Db allele in complex with the N-terminal seven residues of SEV 
(FP7, FAPGNYP) and the dipeptide GL (Paper I, Fig. 2) reveals the asparagine to be lodged 
in the C-pocket, in a similar conformation as in the wt H-2Db/SEV peptide structure (95). 
This further illustrates the influence of the N-terminal part of the peptide in the binding of the 
arginine anchor. 
The GL dipeptide is not the best of the peptide editing dipeptides described in the works by 
Saini et al, who describes the dipeptide GM to be more efficient in their studies (172, 173). 
The GM dipeptide we did not consider as interesting though since our literature review in at 
the start of this study revealed the leucine of the GL to be present in a very interesting mobile 
loop of the tapasin molecule (73). Docking the tapasin structure determined by Dong et al, 
with an MHC-I according to known interaction surfaces revealed this interesting loop to be 
within reach for binding into the MHC-I PBC (73, 176). To study this, we used a portion of 
this loop, EGAGGGGLSK (“TL10”), for refolding with the H-2Db HC and β2m. While this 
first attempt yielded protein, crystallisation trails were unsuccessful, indicating an unstable 
complex. Adding the FP7 peptide to the mix was more successful and a structure was 
determined to 2.15Å (Paper I, S.Tab. 1).  
The structure of the H-2Db with FP7 and TL10 has four complexes in the asymmetric unit. Of 
these, all contain the FP7 peptide and 2 contain a density which can be modelled as a part of 
the TL10 peptide. The remaining two complexes are very close to symmetry related 
molecules, causing the F-pocket to be capped of and the TL10 loop cannot fit. In the F-pocket 
there is still a density, although the identity of the presence here is not known. It does not fit a 
glycerol (used as cryoprotection for the crystals) and it is too large to contain waters. 
Possibly, the crystal has a mixed occupancy in these locations making the identity difficult to 
elucidate. The two complexes where there is density to model parts of the peptide, reveal that 
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most of the TL10 peptide is mobile and cannot be modelled. This can be due to a sterical 
hindrance from the C-terminal of the FP7 peptide, but more likely it is due to the mobility as 
caused by the glycine residues. In modelling the TL10 peptide, making sure that we are 
satisfied it is the leucine of TL10 binding to the F-pocket was a priority. The other 
possibilities were the N-terminal glutamate or aspartate, the C-terminal lysine or parts of the 
FP7 peptide. The F-pocket of H-2Db is hydrophobic in nature, and the anchor positions as 
described in table 1 of this thesis, reveal that many of the charged residues are deleterious for 
a peptide at the F-pocket binding C-terminal position. Accordingly, neither of the TL10 
residues in the N- or C-terminal were advantageous when modelled in the F-pocket of the 
structure, as compared to the modelling of the leucine. Attempting to model the FP7 in the F-
pocket was futile, not only due to worsened statistics but also due to sterical clashes with the 
other FP7, which had a clear density. 
To determine the influence of this loop for peptide loading into the MHC-I, our collaborators 
in the Springer laboratory at Jacobs university in Bremen used a cell-based assay. They used 
tapasin deficient mouse ear fibroblasts transduced with different mutants of the tapasin gene. 
For each mutant, the levels of H-2Db and H2Kb was measured on the cell surface by flow 
cytometry (Paper I, Fig. 4). For H-2Kb, mutating the leucine of TL10 to alanine reduced the 
surface expression with 50%, while the levels were not affected for H-2Db. Other than that, 
the levels of MHC-I expression were not affected if the leucine was present when making 
more drastic reductions of the loop size. Not until a total of six amino acids were removed, 
including the leucine, the surface expression was significantly altered. While the effect of 
larger deletions could be due to the loss of structural integrity to the tapasin protein, these 
results further support the importance of leucine in the peptide loading. It also suggests that 
the tapasin affects the alleles differently. For human alleles, variations in tapasin dependence 
has been shown (177-179). For murine alleles, the tapasin dependence has been studied in a 
human cell-line expressing human tapasin. In this case, the alleles showed equal tapasin 
dependence. (180). This study was however done in the presence or complete removal of 
tapasin (180), whereas the studies on human MHC-I allele dependence was done studying 
single polymorphisms in the MHC-I PBC (177-179). As such, the effect of single mutations 
on peptide loading of tapasin in the murine setting is not elucidated and further studies of the 
effect of point mutations have the potential to reveal more details on the tapasin peptide 
editing mechanism. 
Based on the results in this study and the results in recent studies of TAPBPR and the PLC, 
as discussed in section 2 earlier in this thesis, figure 5 in Paper I describes a model of peptide 
selection assisted by tapasin. In this model the tapasin keeps the MHC-I in an open peptide 
accessible position by binding to the F-pocket with the TL10 loop (aka scoop loop after the 
naming of Thomas and Tampé (68)) and the jack hairpin underneath the PBC. The N-
terminal part of the tapasin binds into the PBC and if the affinity is good enough it competes 
out the tapasin and the stable MHC-I complex is formed. 
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4.2 PAPER II – THE MHC CLASS I CANCER-ASSOCIATED NEOEPITOPE 
TRH4 LINKED WITH IMPAIRED PEPTIDE PROCESSING INDUCES A 
UNIQUE NONCANONICAL TCR CONFORMER 
This paper concerns the first identified TEIPP peptide Trh4 (149). This peptide has an 
unconventional sequence for a H-2Db binding epitope (see table 1 above and (12)). The 
sequence (MCLRMTAVM) contains four sulphur-containing residues and two anchor 
positions are unconventional. Position 2, a cysteine, is usually deleterious in this position 
according to the statistics of iedb.org and the extremely dominant anchor in position 5 is a 
tolerated methionine instead of a conventional asparagine. We determined the crystal 
structure of the H-2Db/Trh4 complex to 2.25Å (Paper II, S.Tab. I). The anchor positions are 
utilised as for a canonical peptide, meaning that p2C and p5M are still interacting with the B- 
and C-pockets (Paper II, Fig. 1A). The peptide binds to the PBC utilising several sulphur-π 
interactions (Paper II, Fig. 1B). Sulphur-π interactions are a group of interactions between 
the sulphurs in methionine or cysteine and an aromatic ring. The optimal interaction distance 
is 3.6-4.3Å with an angle of 30-90° from the diagonal of the plane of the aromatic ring (181-
183). 
In studying the effect of the sulphurs in Trh4, derivates of cysteine and methionine were used. 
These were α-aminobutyric acid (ABU), a cysteine where the sulphur is exchanged for -CH3 
(methyl), and norleucine (NLE), where the sulphur of methionine is exchanged for a -CH2 
methyl group. These unconventional residues have the same overall size as the natural amino 
acids, thereby any differences should not be due to sterical differences. We used two methods 
to determine the stability of H-2Db in complex with these epitopes. The first one (Paper II, 
Fig. 3A and 3B) were established in the beginning of the 1990’s and makes use of the TAP 
deficient RMA-S cell-line (146). The method in based on the fact that the TAP-deficient cell-
line, when grown in 26°C can be loaded with exogenously added peptides. In this assay, the 
peptide of interest is added to the RMA-S culture for 12 h after which the peptide is washed 
away, and the cells are incubated in 37°C for 1 hour in medium containing the Golgi 
transport inhibitor Brefeldin A. The cells are then sampled as certain time points after this, 
stained with antibodies against the H-2Db on the surface and the expression is quantified 
using flow cytometry. Since the golgi transport is inhibited, the H-2Db levels on the surface 
will be reduced in a manner related to the stability of the pMHC complex. From this the time 
it takes or the expression levels to reduce to 50% of the initial levels can be read as a stability 
measurement (171, 184). The second method is Circular Dichroism (CD). While the cell-
surface stability measurement is a cell biology-based method, CD is a strictly biophysical 
method. The basis of CD is the angle of the peptide bond in the protein, which when in a 
circularly polarised beam of light will absorb certain angles differently for a single 
wavelength. Changing the wavelength will give a spectrum which is characteristic depending 
on the amount of α-helix and β-sheet content in the protein. When heating a protein sample, 
this spectrum will change as the secondary structural elements of the protein denaturates. As 
such, we can follow the denaturation and find a melting temperature by measuring in set 
intervals as the temperature of the sample is slowly increased and calculate a melting 
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temperature (185). These two methods have their own advantages and disadvantages. The 
most positive aspect of the cell-based assay, is that the measurement is performed in a more 
native setting. The MHC-I molecule has the natural glycosylation patterns and the 
surroundings that are normal on the surface of the cell. The most positive side of the CD-
measurement is the controlled setting; the exact concentration, the purity and the buffer is 
known beyond any doubt. In the CD measurement, however, the protein is recombinantly 
made, meaning that any interaction in the natural environment of the cell surface is lost. But 
on the other hand, the cell-assay is subject to potential confounders outside the control of the 
experimentalist, since health of a cell-culture, exact composition of the growth media etc, are 
more difficult to control than a recombinant protein in solution. 
The results of these assays were more pronounced in the cell-based assay than in the CD-
measurements, but both assays indicated that mutated versions where the sulphur-π 
interactions were abrogated induce a less stable H-2Db/peptide complex (Paper II, Fig. 3). 
Determination of the crystal structures of H-2Db/Trh4-p2ABU and H-2Db/Trh4-NLE (Paper 
II, Fig. 4, S.Tab I and S.Tab 2) revealed the structures of both complexes to absolutely 
similar to the H-2Db/Trh4, ruling out changes in the protein structure as a reason for the 
observed stability differences. 
Paper II, figure 5 illustrates the results in an IFN-γ release assay where peptide-loaded mouse 
splenocytes have been incubated with the H-2Db/Trh4-specific T-cell LnB5. This assay is a 
measurement of the immunogenicity of a specific APL. Generally, mutation of methionine to 
norleucine does not affect the immunogenicity of the complex, unless all of them are 
simultaneously mutated which causes a small increase in immunogenicity (Paper II, Fig. 
5A). Similarly, the sulphur-π interaction of peptide position 2 with the MHC heavy chain has 
only a small effect on immunogenicity (Paper II, Fig 5B). Both these effects are marginal in 
comparison with other APLs tested. An alanine mutation APL scan of the Trh4 peptide 
shows large differences in the immunogenicity of the peptides. Together with the structure of 
H-2Db/Trh4 we can assess which of these are due to abrogation of direct interactions between 
the pMHC-I and the TCR of the LnB5 T-cells. The structure reveals that positions p2C, p3L, 
p5M and p9M are buried in the PBC, while the remaining residues are protruding towards the 
solvent. As such, we can conclude from this experiment that p5L, p6T and p8V are essential 
to LnB5 interactions, while the loss of the side chains of p3L, p5M and to some extent p9M 
are essential to the integrity of the complex (Paper II, Fig. 5C). 
An essential observation in the paper is that the mutation of p5M to the canonical anchor 
asparagine is deleterious to the immunogenicity of the epitope. This is evident in figure 5D, 
where the IFN-γ levels are completely nulled by the p5N APL of Trh4. This is likely not due 
to the peptide not binding to the H-2Db on the cell surface, since this peptide is tested in the 
cell-based stability assay and exhibits similar stability to the canonical dominant gp33 peptide 
from LCMV (Paper II, Fig. 3A). However, in figure 2 of this paper, the structural 
comparison of H-2Db/Trh4 and H-2Db/gp33, where the Cα-atoms of the HC of the α1 and α2 
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domains are overlaid, revealed that the only difference in the atoms of the HC is a shift in the 
H155 and T156 residues, which are essential to the TCR recognition.  
4.3 PAPER III – THE IMMUNOGENICITY OF A PROLINE-SUBSTITUTED 
ALTERED PEPTIDE LIGAND TOWARD THE CANCER-ASSOCIATED 
TEIPP NEOEPITOPE TRH4 IS UNRELATED TO COMPLEX STABILITY 
This paper also concerns the Trh4 TEIPP epitope studied in paper II. Here, however, the p3P 
APL strategy for increasing immunity of the epitope is utilised. This strategy was first 
introduced in a 2009 paper by van Stipdonk et al, where it was demonstrated to increase the 
immunogenicity of the gp100 epitope from malignant melanoma (166). The first observation 
in this paper is that the Trh4p3P APL peptide indeed is significantly more immunogenic than 
the Trh4 wt peptide (Paper III, Fig. 1). Mice that were injected with LnB5 T-cells (Trh4 
specific) and vaccinated with the Trh4p3P epitope showed a remarkable expansion of these 
T-cells, and at the maximum response 80% of the T-cells present in the mouse were LnB5 T-
cells. Vaccination with the Trh4 wt epitope gave a maximum expansion to 5% on the total T-
cells (Paper III, Fig. 1C). The Trh4p3P vaccinated mice also showed higher specific killing 
of Trh4 wt loaded cells in an in-vivo killing assay (Paper 3, Fig. 1F). 
Commonly when working with APLs the aim is to increase the pMHC-I complex stability 
(164, 165). However, this is not the case with the Trh4p3P peptide. The H-2Db/Trh4p3P was 
determined to be significantly less stable than the H-2Db/Trh4 in a cell-surface stability assay 
preformed as described for paper II. In this case, the CD-based stability assay showed a 
reduction in stability, but even if this reduction was very small at 1.65 °C, the change was 
statistically significant. Not only is the reduced stability of the H-2Db/Trh4p3P interesting 
from an immunological viewpoint, but it is also interesting to note such a big difference in the 
results of the two methods. There is also a secondary difference in these methods that are not 
discussed previously for paper II. While both assays are measuring stability, the cell-based 
assay is measuring the spontaneous collapse and internalisation of the pMHC-I under stable 
conditions and the CD-based assay are measuring the collapse of the pMHC-I complex under 
the stress of raised temperature. The timespan of the experiments is also very different. An 
interesting way to determine a correlation between these two methods would be to measure 
the denaturation of the protein complexes by CD with a steady temperature equivalent to the 
cell-based assay, i.e. 37°C. This could be the reason for the differences observed in this 
paper. Determining the structure of the H-2Db/Trh4p3P complex revealed that the mutation 
from leucine to proline in position 3 leads to a conformational change in the methionine at 
position 5. This conformation change leads the distance between the aromatic ring in HC 
residue Y166 and the sulphur in the methionine to become too large for efficient interaction 
(181-183). The structures also reveal that the surfaces of both the complexes are very similar. 
Unfortunately, there is not much evidence in the structures as to why these two complexes 
have different immunogenicity.  
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4.4 PAPER IV – CRYSTAL STRUCTURES OF H-2Db IN COMPLEX WITH THE 
LCMV-DERIVED PEPTIDES GP92 AND GP392 EXPLAIN PLEIOTROPIC 
EFFECTS OF GLYCOSYLATION ON ANTIGEN PRESENTATION AND 
IMMUNOGENICITY 
Two H-2Db restricted epitopes from the Lymphocytic choriomeningitis virus (LCMV) were 
identified in 1998, GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL) (186). Both contain 
a N-glycosylation site (Asn-X-Ser/Thr, X ≠ Pro) and which are glycosylated in the native 
protein (187). The glycans have opposite effects on GP92 and GP392 H-2Db epitopes. The 
sub-dominant peptide GP92 and its modified forms GlcNAc-GP92 and the deglycosylated 
variant D-GP92 are all immunogenic (188). GP392 is immunogenic only in the unmodified 
form, meaning that in vaccination attempts with the peptides and its modified versions, T-cell 
could not be raised against GlcNAc-GP392 or D-GP392 (189).  
The crystal structures of H-2Db in complex with the unmodified versions GP92 and GP392 
were determined to 2.4Å and 2.5Å respectively (Paper IV, Tab. 1). Both bind with the 
canonical asparagine as an anchor (12) and the N-terminal anchors are of the preferred spices 
(leucine and isoleucine). For GP92 the glycosylated residue protrudes from the surface 
(Paper IV, Fig. 4), while for the GP392, the glycosylated asparagine is lodged as the anchor 
in the C-pocket (Paper IV, Fig. 5). This does not make it impossible for the peptide to still 
bind as previously demonstrated for another epitope in a publication by Glithero et al (95). 
However, since this peptide is not immunogenic enough for T-cells to be raised against it, and 
show no binding to H-2Db (189), it is unlikely that this possible conformation is preferred 
(Paper IV, Fig. 5C).  
Another notable discussion in this paper provides insights to the possibilities and problems in 
the presentations of glycosylated peptides as a neoepitopes. The GlcNAc-GP92 is not 
presented on LCMV-infected cells (188), even though it is likely to be the major species of 
the protein (187). Instead, GP92 is detected, meaning that either there is a significant amount 
of unglycosylated protein, or providing further evidence for the DRiP hypothesis. The fact 
that GlcNAc-GP92 is not presented could be due to deglycosylation prior to proteasomal 
cleavage. This illustrates the unpredictability of glycopeptide processing and presentation. 
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5 FINAL REMARKS 
Additional tiny pieces of the grand puzzle that is biology are added through this thesis. The 
mechanism of peptide editing of tapasin is far from determined, and as our results in paper I 
demonstrate, it is not certain that the mechanism is exactly similar for different MHC-I 
alleles. As tapasin deficiency is a potential immune escape mechanism for cancers, different 
alleles might be differently affected by a potential mutation. The formation of potentially 
therapy-exploitable TEIPP epitopes can potentially vary through the population. However, as 
shown in paper II and III, we can still be surprised by new discoveries that are not following 
conventional ideas of peptide motifs and immunogenicity. I believe that proceeding to study 
peptide selection mechanisms and unexpected peptides, thus expanding little by little the 
knowledgebase, will eventually lead to the discovery of the next successful therapy. 
 

  33 
6 ACKNOWLEDGEMENTS 
Enskede, Stockholm, 2018-03-25 
Closing in on the end of this journey, the PhD studies, I cannot be more grateful to the people 
who in things great and small have provided me the things I have needed along the way. No 
matter if it has been support in matters big and small, cheers, friendship, hugs or a smile, I 
hereby offer my sincerest thank you to: 
Adnane Achour, For taking me under your wings and providing me with all the 
opportunities to develop, learn science and understanding scientific life. Thank you! 
Tatiana Sandalova; I wish I could really let you know how much I appreciate the support, 
the help and the wisdom I have received from you. I hope you know how much I really mean 
this: Спасибо 
My co-supervisors: 
Per-Åke Nygren, your fascination and your passion for science are infectious and inspiring! 
Thank you for being my co-supervisor! It has been an honour! 
Benedict Chambers, always a smile and a laugh, and behind that is a vast library of 
knowledge on everything immunology. Fantastic! 
Adil Doganay Duru. My academic big brother, Thank you for giving me the opportunity to 
join you at NSU. Those 6 months was more than learning techniques and science. You and 
your group there gave me more than I can express… Thank you! 
My mentor; Rosemarie Friemann, I think the most important thing with a mentor is to have 
a friend to talk to that knows everything about how things are and who always is by your 
side. Someone with who you don’t need to have a filter. Thank you for being my mentor! 
The Achour lab past and present; 
Anatoly, who really knows everything in the lab and taught me loads; Tim, without who the 
lab wouldn’t function and be truly empty; Gena, our sweetest and kindest uncle; Jeremie, 
my dear friend who always makes things more fun; Xiao, my sister and my friend, whose 
support and friendship I am lucky to have; Renhua, I’ll miss working next to you, not only 
because you are one of the smartest people I know but also one of the funniest; Angel, whose 
laughter makes us all smile; and Christina, you are not always here, but you always makes 
me happy when you are! 
Students and visitors in the Achour lab: Anca, Nicole, Panos, Beatrice, Sofia, Benedetta, 
Linnea, Maya, Sebastian, Dahao, Imre, Liz, Nils, Amy… Did I forget someone??? 
The people of Nova Southeastern University: You became like a family away from home and 
your welcoming me into the CTI was fantastic: 
 34 
Canan, Ben, Anna-Maria, Wendy, Ayhan, Susy, Michelle, Robin, Chris… Such 
awesome people Adil work with… You guys are just… I don’t know… Awesome, Amazing, 
Great… All of it in the same time?  
Vlad, Fiorella and Hunter; I’m so looking forward to joining you in the lab.  
Rich, Jill, Sara, Shannon, Emily, Javier, Ron, Julia and Marliese. 
Kim, you rock! The Flow core is just the coolest place in NSU. Let’s go teach T-Rex to shoot 
some zombies! 
Renee… Sunday funday… Halloween… We had so much epic fun and soon we will add 
more! 
Facilities and collaborators; Protein Science facility, always welcoming and friendly; The 
animal facility at MTC (that is no more) It was a privilege to learn from you!; Petter 
Brodin and the CyTOF facility and especially Jaromir Mikes for introducing me to the big 
scary Flow machine.  
Those who lighten up Scilife outside my group; The gamma 4 community, you are all 
awesome. Nobody mentioned, nobody forgotten, but I would like to mention all of you!; 
Alpha 4 for the year we were there; The Scilife administration; The people who spend their 
free time making sure there is a pub; And of course, Delta cafeteria (Titti och Jossan) and 
the reception. 
Those who kept in touch from the olden days (at LIU), Marie, Madhanagopal and Anna, I 
miss you. 
Rachel, beamtimes was the most fun with you. A few days in Berlin and we are like old 
friends!  
While I must admit there are so many I consider my friends at Scilife and I thank you all, 
three of you have become close friends. Adeline, Gabriele (Make a cat! Haha) and Sabina.  
Annette; Du sa en gång när jag hade ett stort val i mitt liv; ”Du kan inte ångra dig Ida; För du 
vet aldrig hur det hade blivit om du valt annorlunda.” Fantastisk lärdom från en fantastisk 
människa.  
Jocke och Andreas: Ni är som bröder till mig, saknar er så mycket! Varför måste vi vara 
halva världen bort from varandra? Hoppas innerligen att alla mina födelsedagar lever upp till 
den standarden vi satte runt min 30-års dag, men jag tror det blir svårt.  
Angeles Shunashy: Living up to your name at all times! I’m so lucky to have you as a 
friend! 
Tagrid: Were we twins in a previous life? We are far too similar… ;-) Love you, sis! 
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Min familj, alltid viktigast för utan er hade jag inte varit här alls. Älskar er alla!  
Morfar; Vi har sådan enorm tur som får ha dig kvar!  
Lovisa; Hur tackar man den mest underbara människan i världen? 
Mamma och Pappa; Fantastiska, härliga och alltid där! Tack för allt! 
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